Helen Torley - Dec 13, 2022 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role
PRESIDENT AND CEO, Director
Signature
/s/ James R. Oehler, Attorney-in-Fact
Stock symbol
HALO
Transactions as of
Dec 13, 2022
Transactions value $
-$1,743,302
Form type
4
Date filed
12/15/2022, 06:12 PM
Previous filing
Nov 17, 2022
Next filing
Jan 19, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HALO Common Stock Options Exercise $147K +10K +1.7% $14.66 597K Dec 13, 2022 Direct F1
transaction HALO Common Stock Sale -$557K -9.51K -1.59% $58.64 588K Dec 13, 2022 Direct F1, F2
transaction HALO Common Stock Sale -$29.1K -493 -0.08% $59.12 587K Dec 13, 2022 Direct F1
transaction HALO Common Stock Options Exercise $147K +10K +1.7% $14.66 597K Dec 14, 2022 Direct F1
transaction HALO Common Stock Sale -$583K -10K -1.67% $58.30 587K Dec 14, 2022 Direct F1, F3
transaction HALO Common Stock Options Exercise $147K +10K +1.7% $14.66 597K Dec 15, 2022 Direct F1
transaction HALO Common Stock Sale -$522K -9.1K -1.52% $57.29 588K Dec 15, 2022 Direct F1, F4
transaction HALO Common Stock Sale -$52.1K -896 -0.15% $58.20 587K Dec 15, 2022 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HALO Option to Purchase Common Stock Options Exercise -$147K -10K -8.33% $14.66 110K Dec 13, 2022 Common Stock 10K $14.66 Direct F1, F6
transaction HALO Option to Purchase Common Stock Options Exercise -$147K -10K -9.09% $14.66 100K Dec 14, 2022 Common Stock 10K $14.66 Direct F1, F6
transaction HALO Option to Purchase Common Stock Options Exercise -$147K -10K -10% $14.66 90K Dec 15, 2022 Common Stock 10K $14.66 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on September 7, 2022 in accordance with Rule 10b5-1.
F2 Represents a weighted average sales price per share. The shares were sold at prices ranging from $58.11 to $59.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Represents a weighted average sales price per share. The shares were sold at prices ranging from $58.11 to $58.49. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Represents a weighted average sales price per share. The shares were sold at prices ranging from $57.00 to $57.98. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5 Represents a weighted average sales price per share. The shares were sold at prices ranging from $58.02 to $58.22. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6 Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was January 6, 2014.